Systems and methods systems related to electrosurgical wands with screen electrodes

Information

  • Patent Grant
  • 9526556
  • Patent Number
    9,526,556
  • Date Filed
    Friday, February 28, 2014
    10 years ago
  • Date Issued
    Tuesday, December 27, 2016
    8 years ago
Abstract
An electrosurgical wand for treating tissue at a target site within or on a patient's body is described, having an elongate shaft with a handle and a distal end portion. The distal end portion has an active electrode, an insulative spacer body and a return electrode; the active electrode supported by the insulative spacer body and spaced away from the return electrode. The active electrode has both lateral and medial edge surfaces. The insulative spacer body has an aspiration cavity fluidly connected with an aspiration lumen, and at least one tapered aperture extending beyond at least one of the electrode medial edge surfaces and directed to the aspiration cavity.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

None.


FIELD OF THE INVENTION

The present invention relates generally to the field of electrosurgery, and more particularly to apparatus and methods for applying high frequency voltage to ablate tissue. More particularly, the present invention relates to apparatus and methods for securing a substantially flat screen-type active electrode to the distal tip of the shaft of an electrosurgical instrument and methods of fluid aspiration.


BACKGROUND

Electrosurgical systems are used by physicians to perform specific functions during surgical procedures. For example, in an ablation mode electrosurgical systems use high frequency electrical energy to remove soft tissue such as sinus tissue, adipose tissue or other tissue such as meniscus, or cartilage or synovial tissue in a joint.


Conventional electrosurgical methods are widely used because they generally achieve hemostasis and reduce patient bleeding associated with tissue cutting operations while improving the surgeon's visibility of the treatment area. Many of the electrosurgical devices used in electrosurgery include a method of removing fluid, debris and bubbles from the field, so as to improve the clinician's visibility around the target tissue area. However, in the case of some electrosurgical devices where sufficient fluid is required to achieve certain clinical effects, such as ablation, fluid removal needs to be balanced or targeted in optimal locations. This may allow sufficient fluid for vapor layer or plasma generation while minimizing debris and bubbles in the field. Many devices also make use of a screen-type active electrode which is typically cut, or etched, from a sheet of conductive material. These electrosurgical devices and procedures, however, may suffer from a number of disadvantages. For example, screen-type active electrodes typically require some method of securement to an insulative body and furthermore to the distal tip of the device itself. Failure to adequately secure the screen electrode to the insulative body may result in improper device function.


Prior attempts to secure the screen active electrode to the insulative body have involved mechanical, thermal, and chemical means or various combinations thereof. Numerous mechanical forms of securement have been utilized, while adhesives have been used as a chemical form of joining, and welding the screen may provide a thermal method of joining. These mechanical joining methods may also include the use of plastic, or non-recoverable, deformations of the materials being used for securement. However, even in combination with other joining methods, all methods for fixation provide solutions that typically are challenged over extended periods of use, due to thermal degradation and plasma degradation. Optimum positioning of the screen electrode fixation with these methods of degradation therefore must be incorporated.


Accordingly, devices and methods which allow targeted fluid aspiration relative to ablation surfaces or edges are desired. Additionally, devices for the securement of flat screen active electrodes to the insulative body of an electrosurgical instrument while maintaining electrical connections through the insulative body are desired. In particular, mechanical methods for providing durable securement of an electrically connected screen active electrode to the insulative body at the distal tip of an electrosurgical device, while providing enhanced electrosurgical operating parameters are desired.


SUMMARY OF THE INVENTION

The present invention provides systems, apparatus and methods for aspirating fluid, debris and gas bubbles from the surgical field and the surgeon's field of view with minimal interruption to the vapor layer. The present disclosure also provides systems, apparatus and methods for mechanically securing a screen type active electrode to the insulative body at the distal tip of an electrosurgical device. Further the present disclosure provides systems and apparatus for creating high current density with internal pointed geometries to decelerate wear on a screen electrode.


In one aspect of the invention, the present disclosure describes an electrosurgical wand for treating tissue using a high frequency voltage delivered to a target site within or on a patient's body. The wand includes an elongate shaft with a handle end and a distal end portion, the distal end portion having an electrode assembly and an insulative spacer body. The electrode assembly includes both a substantially flat active screen electrode and a return electrode spaced from the active screen electrode. The return electrode may be spaced proximally from the active screen electrode and may be part of the elongate shaft. The active electrode is intended to contact tissue and has a relatively large tissue contacting surface and a perimeter or edge surface. The insulative spacer body contacts tissue in places, and also serves to support and electrically insulate the active screen electrode. An aspiration cavity is disposed within the spacer body with an elongate opening at the tissue contacting surface partially covered by the active screen electrode, while a portion of the elongate cavity opening extends beyond a portion of the screen electrode edge surface. The tissue contacting surface includes a first aspiration aperture having a first aperture perimeter, a portion of the first aperture perimeter being defined by part of the edge surface of the screen electrode and also part of the aspiration cavity.


Another configuration of the electrosurgical device according to the present disclosure is an electrosurgical wand for treating tissue at a surgical site with an elongate housing, defining a handle end and a tissue contacting surface at a distal end. Part of the tissue contacting surface includes an active screen electrode which is disposed on an insulative spacer, this spacer also making up part of the tissue contacting surface. The active screen electrode includes at least one lateral edge surface, free of any asperities such as surface geometry or texture that may create an area of high current density such as pointed features or roughened surface, and medial surfaces such as distal and proximal edge surfaces that have at least one asperity such as one pointed geometry feature or area of higher current density. The tissue contacting surface also includes a first aspiration aperture spaced at a discrete location away from the at least one lateral edge surface so as to not disrupt any plasma or vapor layer proximate the lateral edge surface. This aperture is in fluid communication with an aspiration lumen disposed within the wand and may remove any debris or gas bubbles from the surgical site. This first aperture has a perimeter that includes a portion of an insulating spacer cavity and a portion of either the electrode distal edge surface or the electrode proximal edge surface.


In another aspect of the disclosure, a method of treating a target tissue using an electrosurgical wand is described, the method including placing a distal end portion of the wand near a target tissue, the distal end portion including a substantially flat active screen electrode being supported by an insulative spacer. A high frequency voltage may then be applied between the active electrode and a return electrode that is spaced away from the active electrode, the high frequency voltage is sufficient to generate a vapor layer near a tissue contacting surface of the active electrode. The distal end portion may then be oriented so that a lateral edge surface of the active electrode is near the target tissue so as to use this edge surface, primarily to treat the target tissue. Tissue fragments and gas bubbles may then be aspirated away through at least one aspiration aperture that is located in a discrete area that is spaced away from the lateral edge surface. This is so as to not disrupt the vapor layer proximate the active electrode lateral edge surface, to therefore maintain a uniform vapor layer near the lateral edge surface so as to create a more consistent electrosurgical tissue effect. The at least one aspiration aperture has a portion of its perimeter made up by the active screen electrode and a portion by a spacer aspiration cavity.





BRIEF DESCRIPTION OF THE DRAWINGS

For a detailed description of exemplary embodiments, reference will now be made to the accompanying drawings in which:



FIG. 1 shows an electrosurgical system in accordance with at least some embodiments;



FIG. 2 shows an electrosurgical wand in accordance with at least some embodiments;



FIG. 3a shows a perspective view of a wand distal end in accordance with at least some embodiments;



FIG. 3b illustrates a view of a wand contact surface in accordance with at least some embodiments;



FIG. 3c shows a wand distal end cross-sectional view in accordance with at least some embodiments;



FIG. 4 shows a perspective view of an insulating spacer of a wand in accordance with at least some embodiments;



FIG. 5 shows an elevation view of the distal end of a wand treating tissue in accordance with at least some embodiments;



FIG. 6 shows a method of treating tissue in accordance with at least some embodiments; and



FIG. 7 shows a method of treating tissue in accordance with at least some embodiments.





NOTATION AND NOMENCLATURE

Certain terms are used throughout the following description and claims to refer to particular system components. As one skilled in the art will appreciate, companies that design and manufacture electrosurgical systems may refer to a component by different names. This document does not intend to distinguish between components that differ in name but not function.


In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . . ” Also, the term “couple” or “couples” is intended to mean either an indirect or direct connection. Thus, if a first device couples to a second device, that connection may be through a direct connection or through an indirect connection via other devices and connections.


Reference to a singular item includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural references unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement serves as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Lastly, it is to be appreciated that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.


“Active electrode” shall mean an electrode of an electrosurgical wand which produces an electrically-induced tissue-altering effect when brought into contact with, or close proximity to, a tissue targeted for treatment, and/or an electrode having a voltage induced thereon by a voltage generator.


“Return electrode” shall mean an electrode of an electrosurgical wand which serves to provide a current flow path for electrons with respect to an active electrode, and/or an electrode of an electrosurgical wand which does not itself produce an electrically-induced tissue-altering effect on tissue targeted for treatment.


Where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such material by virtue of prior invention.


DETAILED DESCRIPTION

The present invention provides systems and methods for selectively applying electrical energy to a target location within or on a patient's body. The present invention is particularly useful in procedures where the tissue site is flooded or submerged with an electrically conducting fluid, such as arthroscopic surgery of the knee, shoulder, ankle, hip, elbow, hand or foot. In other procedures, the present invention may be useful for collagen shrinkage, ablation and/or hemostasis in procedures for treating target tissue alone or in combination with the volumetric removal of tissue. More specifically, the embodiments described herein provide for electrosurgical devices characterized by a substantially flat and relatively thin screen active electrode disposed at the distal tip of the device. Additionally, the present embodiments include apparatus and methods for the targeted aspiration of fluid and debris away from the surgical field as well as methods of mechanical securement of the screen electrode and wear resistant design features to the screen electrode. These embodiments may extend the operating period of the electrosurgical device by providing a more wear resistant electrode to plasma and a more robust electrode securement method of attachment. These embodiments may also improve the surgeon's visibility of the surgical field while minimizing any disruption to a vapor layer around the screen electrode and hence any disruption to the intended tissue effect.


Before the present invention is described in detail, it is to be understood that this invention is not limited to particular variations set forth herein as various changes or modifications may be made to the invention described and equivalents may be substituted without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such material by virtue of prior invention.


Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Last, it is to be appreciated that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.



FIG. 1 illustrates an electrosurgical system 100 in accordance with at least some embodiments. In particular, the electrosurgical system 100 comprises an electrosurgical wand 102 (hereinafter “wand 102”) coupled to an electrosurgical controller 104 (hereinafter “controller 104”). The wand 102 comprises an elongate housing or elongate shaft 106 that defines distal end 108. The elongate shaft 106 further defines a handle or proximal end 110, where a physician grips the wand 102 during surgical procedures. The wand 102 further comprises a flexible multi-conductor cable 112 housing one or more electrical leads (not specifically shown in FIG. 1), and the flexible multi-conductor cable 112 terminates in a wand connector 114. As shown in FIG. 1, the wand 102 couples to the controller 104, such as by a controller connector 120 on an outer surface of the enclosure 122 (in the illustrative case of FIG. 1, the front surface).


Though not visible in the view of FIG. 1, in some embodiments the wand 102 has one or more internal fluid conduits coupled to externally accessible tubular members. As illustrated, the wand 102 has a flexible tubular member 116, used to provide aspiration at the distal end portion 108 of the wand. In accordance with various embodiments, the tubular member 116 couples to a peristaltic pump 118, the pump being illustratively shown as an integral component with the controller 104. In other embodiments, an enclosure for the peristaltic pump 118 may be separate from the enclosure 122 for the controller 104 (as shown by dashed lines in the figure), but in any event the peristaltic pump is operatively coupled to the controller 104. In the context of the various embodiments, the peristaltic pump 118 creates a volume-controlled aspiration from a surgical field at the distal end portion 108 of the wand 102.


Still referring to FIG. 1, a display device or interface device 130 is visible through the enclosure 122 of the controller 104, and in some embodiments a user may select operational modes of the controller 104 by way of the interface device 130 and related buttons 132. In some embodiments the electrosurgical system 100 also comprises a foot pedal assembly 134. The foot pedal assembly 134 may comprise one or more pedal devices 136 and 138, a flexible multi-conductor cable 140 and a pedal connector 142. While only two pedal devices 136 and 138 are shown, one or more pedal devices may be implemented. The enclosure 122 of the controller 104 may comprise a corresponding connector 144 that couples to the pedal connector 142. A physician may use the foot pedal assembly 134 to control various aspects of the controller 104, such as the operational mode. For example, pedal device 136 may be used for on-off control of the application of radio frequency (RF) energy to the wand 102. Further, pedal device 138 may be used to control and/or set the mode of ablation of the electrosurgical system. In certain embodiments, control of the various operational or performance aspects of controller 104 may be activated by selectively depressing finger buttons located on handle 110 of wand 102 (the finger buttons not specifically shown so as not to unduly complicate the figure).


The electrosurgical system 100 of the various embodiments may have a variety of operational modes. One such mode employs Coblation® technology. In particular, the assignee of the present disclosure is the owner of Coblation® technology. Coblation® technology involves the application of RF energy between one or more active electrodes and one or more return electrodes of the wand 102 to develop high electric field intensities in the vicinity of the target tissue. The electric field intensities may be sufficient to vaporize an electrically conductive fluid over at least a portion of the one or more active electrodes in the region between the one or more active electrodes and the target tissue. The electrically conductive fluid may be inherently present in the body, such as blood, or in some cases extracelluar or intracellular fluid. In other embodiments, the electrically conductive fluid may be a liquid or gas, such as isotonic saline. In some embodiments the electrically conductive fluid is delivered in the vicinity of the active electrodes and/or to the target site by the wand 102.


When the electrically conductive fluid is heated to the point that the atoms of the fluid vaporize faster than the atoms condense, a vapor or gas is formed. When sufficient energy is applied to the vapor or gas, the atoms collide with each other causing a release of electrons in the process, and an ionized gas, ionized vapor layer, or plasma is formed (the so-called “fourth state of matter”). Stated otherwise, plasmas may be formed by heating a gas and ionizing the gas by driving an electric current through the gas, or by directing electromagnetic waves into the gas. The methods of plasma formation give energy to free electrons in the plasma directly, electron-atom collisions liberate more electrons, and the process cascades until the desired degree of ionization is achieved. A more complete description of plasma can be found in Plasma Physics, by R. J. Goldston and P. H. Rutherford of the Plasma Physics Laboratory of Princeton University (1995), the complete disclosure of which is incorporated herein by reference.


As the density of the plasma becomes sufficiently low (i.e., less than approximately 1020 atoms/cm3 for aqueous solutions), the electron mean free path increases such that subsequently injected electrons cause impact ionization within the plasma. When the ionic particles in the plasma layer have sufficient energy (e.g., 3.5 electron-Volt (eV) to 5 eV), collisions of the ionic particles with molecules that make up the target tissue break molecular bonds of the target tissue, dissociating molecules into free radicals which then combine into gaseous or liquid species. Often, the electrons in the plasma carry the electrical current or absorb the electromagnetic waves and, therefore, are hotter than the ionic particles. Thus, the electrons, which are carried away from the target tissue toward the active or return electrodes, carry most of the plasma's heat, enabling the ionic particles to break apart the target tissue molecules in a substantially non-thermal manner.


By means of the molecular dissociation (as opposed to thermal evaporation or carbonization), the target tissue is volumetrically removed through molecular dissociation of larger organic molecules into smaller molecules and/or atoms, such as hydrogen, oxygen, oxides of carbon, hydrocarbons and nitrogen compounds. The molecular dissociation completely removes the tissue structure, as opposed to dehydrating the tissue material by the removal of liquid within the cells of the tissue and extracellular fluids, as occurs in related art electrosurgical desiccation and vaporization. A more detailed description of the molecular dissociation can be found in commonly assigned U.S. Pat. No. 5,697,882, the complete disclosure of which is incorporated herein by reference.


In addition to the Coblation® mode, the electrosurgical system 100 of FIG. 1 is also useful for sealing larger arterial vessels (e.g., on the order of about 1 millimeter (mm) in diameter), when used in what is known as a coagulation mode. Thus, the system of FIG. 1 may have an ablation mode where RF energy at a first voltage is applied to one or more active electrodes sufficient to effect molecular dissociation or disintegration of the tissue, and the system of FIG. 1 may also have a coagulation mode where RF energy at a second, lower voltage is applied to one or more active electrodes (either the same or different electrode(s) as the ablation mode) sufficient to heat, shrink, seal, fuse, and/or achieve homeostasis of severed vessels within the tissue.


The energy density produced by electrosurgical system 100 at the distal end 108 of the wand 102 may be varied by adjusting a variety of factors, such as: the number of active electrodes; electrode size and spacing; electrode surface area; asperities and/or sharp edges on the electrode surfaces; electrode materials; applied voltage; current limiting of one or more electrodes (e.g., by placing an inductor in series with an electrode); electrical conductivity of the fluid in contact with the electrodes; density of the conductive fluid; and other factors. Accordingly, these factors can be manipulated to control the energy level of the excited electrons.



FIG. 2 illustrates a view of the wand 102 in accordance with example systems. In the illustrated embodiment the elongate shaft 106 is made of a metallic material (e.g., Grade TP304 stainless steel hypodermic tubing), and in some cases the elongate shaft 106 also defines a return electrode for the system. The wand 102 such as the embodiment shown in FIG. 2 may be designed for surgical procedures involving the knee or hip. The illustrated embodiment's elongate shaft 106 has a circular cross-sectional shape with a bend towards the distal end 108, orienting distal end 108 approximately 40° relative to the elongate axis of the proximal portion of shaft 106. Additionally distal end surface is oriented at an angle to the elongate axis of the shaft 106, cut at approximately a 30° angle relative to the distal end of the shaft 106, to define an oval shaped distal end surface 250 (better illustrated in FIGS. 3a and 3b). This provides for a lower wand distal end profile in order to accommodate space restrictions and posterior anatomy access. For embodiments where the cross-sectional shape of the elongate shaft 106 is circular, the outside diameter may be on the order of about 3 millimeters (mm), but larger and smaller dimensions may be used.


In embodiments where the elongate shaft is metallic, the distal end portion 108, as illustrated in FIG. 3a, may further comprise an electrically insulative spacer 200 coupled to the elongate shaft 106. In some cases spacer 200 is ceramic, but other non-conductive materials resistant to degradation when exposed to plasma may be equivalently used (e.g., glass). Spacer 200 may couple to the elongate shaft 106 in any suitable manner, such as telescoping within an inside diameter of the elongate shaft 106, by telescoping over the elongate shaft 106, and/or by use of adhesive. As shown in FIG. 3c, spacer 200 has a telescoping portion 266 operable to be placed within the internal diameter of the elongate housing 106 and in some cases the spacer may be at least partially held in place by an adhesive. Spacer 200 supports at least one active screen electrode 202 constructed of metallic or electrically conductive material. Spacer 200 thus electrically insulates active electrode 202 from the elongate shaft 106, as the elongate shaft 106 may act as the return electrode 203. In some embodiments, only a portion of elongate shaft 106 is exposed to act as return electrode 203, with the remaining portion of shaft 106 covered with an insulating material.


The illustrative active screen electrode 202 may comprise a conductive material, such as tungsten, titanium, molybdenum, stainless steel, aluminum, gold, copper or the like. Screen electrode 202 may have a diameter in the range of about 0.5 to 8 mm, preferably about 1 to 4 mm, and a thickness of about 0.05 to about 2.5 mm, preferably about 0.1 to 0.5 mm. Screen electrode 202 may have a variety of different shapes, such as the shape shown in FIGS. 3a and 3b, including at least one lateral edge surface 205 having a continuous edge surface free of any asperities such as pointed geometries. Lateral edge surface 205 is laterally spaced away from all aspiration apertures, such as aperture 206, 254 and 252 that are disposed more medially on the wand 102, so that a vapor layer may form adjacent a lateral edge surface 205 and remain relatively undisturbed during any aspiration. Screen electrode 202 may also include medial edge surfaces, such as a distal edge surface 210 and proximal edge surface 212, at least one of which may include at least one asperity such as an internal pointed geometry feature or cusp 214a, b, or some form of pointed or edged surface geometry. A surface asperity such as an internal pointed geometry feature creates a point of higher current density that leads to a preferential point of vapor layer initiation and potentially plasma generation on the active electrode 202. Without cusps 214a, b, vapor layer initiation may require higher voltages. Illustrated best in FIGS. 3a and 3b, active electrode 202 has four inverted cusps 214a of varying sizes disposed on the distal edge surface 210 and another four inverted cusps 214bof varying sizes on the proximal edge surface 212. These are disposed at a specific, distinct location advantageous for enhanced vapor layer formation and potentially subsequent plasma formation, but spaced medially away from lateral edge surfaces 205.


In particular, inverted cusps 214a, b may be defined by curved portions 209 that tangentially intersect at a point 230. Inverted cusps 214a, b have a consistent or uniform shape throughout the thickness of active electrode 202, so that the point of intersection 230 creates an elongated surface or line, with minimal transition or radius between adjacent curved portions 209, through the thickness of screen electrode 202. Inverted cusps 214a, b create a point of vapor layer initiation to improve vapor layer formation and potentially plasma formation, proximate the point of intersection 230 for smooth tissue cutting. Unlike other plasma and vapor layer initiating asperities known in the art, such as externally protruding points or alternatively edges or corners of electrodes, the inverted cusp provides a vapor layer initiation point that minimizes tissue snagging during wand and electrode motion across tissue surfaces during tissue treatment. Additionally, the use of inverted cusps 214a, bas formed by intersection 230 appear to provide the unexpected benefit of more consistent and predicable patterns of active electrode 202 material wear and erosion. Illustrated best in FIG. 3b, inverted cusps 214a and 214b have a variety of depths and curves so that point 230 may be spaced to varying degrees from the electrode distal edge surface 210 or the proximal edge surface 212. It has been found during typical wand operation that the distal edge surface 210 tends to preferentially erode relative to the proximal edge surface 212. One reason for this is as a result of a typical wand orientation during tissue treatment, which leads to a preferred vapor layer initiation at the more distal portion of the electrode 202. The inventors have also found that in this particular orientation the flow rate of fluid drawn into the aspiration aperture is higher at the distal portion of electrode 202 and as drawn into aperture 252. Erosion rates of the material of electrode 202 have been found to be directly related to the proximity of the cusps to areas of higher fluid aspiration. Therefore, adjacent to aspiration apertures with relatively higher rates of fluid flow (e.g., adjacent aperture 252 in the presently describe configuration), distal cusps 214a have a first or reduced depth (d) relative to cusps 214b with a second depth D, or larger depth D to accommodate these differing erosion rates. By adjusting the depth of the cusps in areas with proximity to preferred vapor layer initiation characteristics and higher fluid aspiration rates, the inventors have found that the useful life of electrode 202 may be extended.


Screen electrode 202 may comprise aspiration aperture 206 having sizes and configurations that may vary depending on the particular application. Electrode aspiration aperture 206 will typically be large enough to allow ablated tissue fragments to pass through into an aspiration cavity and suction lumen (described in later figures) within insulative spacer 200 and flexible tubular member 116. Electrode aspiration aperture 206 is disposed in approximately the centre of the active electrode 202 and is spaced away from at least one lateral edge surface 205. Shown here, aspiration aperture 206 is spaced approximately equidistant between the two lateral edge surfaces 205. Screen electrode 202 may also have at least one securing wire aperture 216 sized to receive a securing wire or ribbon 220 operable to secure active screen electrode 202 to spacer 200. Wire or ribbon 220 may comprise a conductive material, such as platinum iridium and is operable to perform multiple functions. Firstly securement wire 220 is electrically connected with cable 112, disposed within elongate shaft 106 as well as active screen electrode 202, so as to be part of the electrical conduit through which the RF controller 104 delivers energy to the active screen electrode 202. Securement ribbon 220 may protrude through the at least one securing wire aperture 216 (as shown in FIG. 3b) and be processed so as to provide both a permanent electrical contact and mechanical securement with the active electrode 202 (shown in welded form 221 in FIG. 3a). This process may include laser spot welding. Securement wire 220 is preferably constructed from a material having a lower melting temperature than the active screen electrode material so as to melt readily during laser spot welding without affecting the grain structure of the active electrode 202. Structural changes to the active electrode 202 may reduce resistance to plasma degradation during the use. Securement wire 220 must also comprise a material with substantial resistance to plasma degradation itself, so that the laser spot weld, and hence mechanical securement and electrical continuity, minimally degrades with use.


Screen electrode 202 has an exposed tissue contacting surface 204, as well as an inner surface (not shown here) that abuts the spacer top surface 250. A portion of spacer top surface 250 also forms part of the tissue contacting surface. Screen electrode 202 abuts spacer top surface 250 with minimal gaps, deterring fluid ingress and energy misdirection. In some embodiments, such as that shown in FIG. 3a, active electrode 202 defines an exposed lateral edge surface 205, free of any asperities or internal pointed geometry 214a, b to allow a side ablative effect for application on certain more sensitive tissue types such as cartilage. Use of the lateral edge surface 205 also allows for maximum visibility of the electrode surface 204 and the associated tissue effect. As shown in FIG. 3c, a cross section A-A of FIG. 3b, active electrode aperture 206 is fluidly coupled to the flexible tubular member 116 (shown in FIG. 3c) via a spacer aspiration cavity 256.


As illustrated best in FIGS. 3b, 3c and FIG. 4, spacer cavity 256 defines an elongate shaped opening at spacer top surface 250. Spacer cavity 256 fluidly communicates with electrode aperture 206 and extends in a proximal and distal direction beyond the proximal edge surface 212 and distal edge surface 210 of active electrode 202, so as to define a distal aperture 252 and proximal aperture 254. Spacer cavity 256 tapers from an elongate opening at the top surface 250 to an approximate circular cross section 255 within spacer 200 which gives cavity 256 an elongated funnel-like shape. Cavity taper may have an angle in the range of about 140-170°, and preferably about a 157° angle relative to the contact surface 204 as shown in FIG. 3c. This angle defines a maximum gap X between the active electrode inner surface 218 and beginning of circular cross section 255 of aspiration conduit, so as to minimize clogging of the aspiration tubing and conduits due to larger debris sizes. Gap X may be in the range of about 0.1 to 1 mm, preferably about 0.3-0.6 mm. Debris or tissue fragments larger than gap X in dimension will become trapped within gap X and continue to be fragmented by the ablative effect proximate active electrode inner surface 218 until the debris or tissue fragment is reduced in size, free to be aspirated through cross section 255 while being less likely to clog any downstream aspiration conduits or lumens, such as lumen 116.


Spacer cavity 256, via apertures 252, 254 and in cooperation with the screen electrode distal and proximal edge surfaces 210 and 212 respectively, define a multitude of aspiration apertures adjacent to or at the electrode contact surface 204, all of which are fluidly connected within cavity 256 of spacer 200. Distal aperture 252 has a continuous perimeter defined partially by the electrode distal edge surface 210 and partially by the distal portion of the spacer cavity 256. As shown in FIG. 3b, the perimeter also includes at least one internal cusp 214a. Proximal aperture 254 has a perimeter defined partially by the electrode proximal edge surface 212, including at least one cusp 214b and partially by a proximal portion of the cavity 256. Proximal aperture 254 extends a first distance “E” beyond active electrode proximal edge 212, while distal aperture 252 extends a second distance “e” beyond active electrode distal edge 210. In order to have a more balanced flow between the distal aperture 252 and proximal aperture 254, it has been found that extension “E” should be larger than extension “e”. This is due to differing aspiration rates between the two apertures (252 and 254) predominantly as a result of the difference in transitions angles, 260 and 262. Looking at FIG. 3c, it can be seen that transition angle 260 defines a shallower angle relative to transition angle 262, and results in a preferential aspiration of debris through the distal aperture 252. Increased aspiration may lead to preferential electrode erosion adjacent the area of increased aspriation, so proximal aperture 254 is therefore relatively larger than distal aperture 252 in order to better balance aspiration flow across the tissue contact surface 204 and to mitigate potential erosion to any particular portion of the active electrode 202 around each aperture.


Spacer apertures 252 and 254 and electrode aperture 206 provide conduits for fluid and gas bubbles to be aspirated away from the area surrounding active electrode 202. During arthroscopic surgical procedures the visual field near the surgical site (i.e., near the active electrode) may be obscured by gas bubbles. That is, the process of ablation via tissue contact with the vapor layer described above creates gas bubbles, and in many situations the gas bubbles are quickly aspirated away so as not adversely affect the visual field. However, excessive aspiration too close to a portion of the active electrode 202 that is treating the target tissue may interrupt the vapor layer and hence the uniformity of ablative tissue effect. Apertures 206, 252 and 254 are therefore spaced away, in discrete locations, from the lateral side edge surface 205. Apertures 206, 252 and 254 are disposed between the lateral side edge surface 205 and the primary surgical field viewing portal so as to effectively remove bubbles created predominantly at lateral edge surface 205 which then naturally elevate towards apertures 206, 252 and 254. This is thought to improve surgeon visibility of the surgical field while minimally impacting the vapor layer near the lateral edge surface 205.


A detailed perspective view of spacer is shown in FIG. 4, in accordance with some embodiments, to better describe spacer cavity 256 and securement wire conduits 258. Spacer cavity 256 may be shaped in an elongate funnel form or plenum within spacer that tapers to a more circular cross section 255 (see in FIG. 3c) at a more proximal location of spacer 200, so as to interface with a fluid tube 116 (shown in FIG. 3c) disposed within elongate shaft. Securement wire conduits 258 may be uniform in cross section and extend axially through the entire thickness of spacer 200 to allow passage for securement wires 220 through spacer 200. Spacer 200, being made from an electrical insulating material, may electrically isolate securement wires 220 (shown in FIG. 3b) from each other as well as from return electrode 203. In alternative embodiments, securement wires 220 may have an electrically insulative coating. Securement wires 220 extend proximally through shaft 106 and may electrically couple with multi-conductor cable 112 within handle 110 (not shown here).



FIG. 5 representatively illustrates in greater detail a typical treatment of a target tissue 300 by use of an embodiment of electrosurgical wand 102 according to the present disclosure. Initially, surgeon may place a spacer lateral side 240 on the tissue and roll wand distal end portion 108 toward spacer lateral edge bevel 241 while applying energy, until a tissue effect is observed. This will occur once electrode lateral edge surface 205 is sufficiently close to target tissue 300, or in contact. As shown, the high frequency voltage is sufficient to convert the electrically conductive fluid 310 between the target tissue 300 and active electrode 202 into a vapor layer 312 or plasma.


During the process, gases 320 and debris will be aspirated through apertures 206, 252 or 254 to a vacuum source (not shown). In addition, excess electrically conductive fluid, and other fluids (e.g., blood) will be aspirated from the target site 300 to facilitate the surgeon's view. Gas bubbles 320 may naturally rise from the vapor or plasma layer 312, upwards or in a medial direction towards apertures 206, 252 or 254 and be removed so as to improve surgeon's target tissue visualization.



FIG. 6 shows a method in accordance with at least some embodiments. In particular, the method starts (block 600) and proceeds to: placing a distal end portion of the wand proximate a target tissue, the distal end portion comprising a substantially flat active screen electrode and an insulative spacer, the screen electrode supported by the spacer (block 602); applying a high frequency voltage between the active electrode and a return electrode spaced away from the active electrode, the high frequency voltage sufficient to generate a vapor layer or plasma proximate a tissue contacting surface of the active electrode (block 604); orienting the distal end portion so that a lateral edge surface of the active electrode is proximate a target tissue and treating the target tissue (block 606); and aspirating tissue fragments and gas bubbles through at least one aspiration aperture disposed in a discrete area spaced away from the lateral edge surface so as to not disrupt the vapor layer or plasma proximate the active electrode lateral edge surface, wherein the at least one aspiration aperture is defined by a portion of the active screen electrode and a portion of a spacer aspiration cavity (block 608). The method may also include at least three aspiration apertures and wherein the step of aspirating further comprises aspirating the tissue fragments and gas bubbles approximately equally through the at least three aspiration apertures, wherein the at least three apertures are coplanar on a plane spaced away from the lateral edge surface and the at least three apertures are approximately evenly spaced and of differing sizes so as to uniformly aspirate along a length of the lateral edge surface. The method may also include generating a vapor layer or plasma proximate a geometric feature capable of creating a point of high current density on the active electrode, wherein the geometric feature may comprise an internal cusp. Thereafter, the method ends (block 610).



FIG. 7 shows a method in accordance with at least some embodiments. In particular, the method starts (block 700) and proceeds to: creating a vapor layer proximate to a first edge surface of an active electrode disposed at the distal end of an electrosurgical wand so as to treat a target tissue, wherein the first edge surface is free from any points of high current density (block 702); drawing fluid and tissue fragments through a first aperture defined by the active electrode only and spaced away from the vapor layer proximate the first edge surface (block 704), drawing fluid and tissue fragments through a second aperture that extends beyond an active electrode edge surface, the second aperture perimeter defined in part by a second edge surface of the active electrode and in part by a portion of an insulating spacer cavity, the second edge surface having at least one internal or external pointed geometry or surface asperity, and wherein the second aperture is also spaced away from the vapor layer proximate the first edge surface of the active electrode and also spaced away from the first aperture (block 706). The method may further comprise drawing fluid and tissue fragments through a third aperture, the third aperture defined in part by a third edge surface of the active electrode and in part by a portion of the insulating spacer cavity and wherein the first, second and third aperture are all fluid coupled. Thereafter, the method ends (block 708).


While preferred embodiments of this disclosure have been shown and described, modifications thereof can be made by one skilled in the art without departing from the scope or teaching herein. The embodiments described herein are exemplary only and are not limiting. Because many varying and different embodiments may be made within the scope of the present inventive concept, including equivalent structures, materials, or methods hereafter though of, and because many modifications may be made in the embodiments herein detailed in accordance with the descriptive requirements of the law, it is to be understood that the details herein are to be interpreted as illustrative and not in a limiting sense.

Claims
  • 1. An electrosurgical wand for treating tissue at a target site within or on a patient's body comprising: an elongate shaft having a handle end and a distal end portion, the distal end portion comprising an active electrode, an insulative spacer body and a return electrode, wherein the active electrode is supported on the insulative spacer body and is spaced away from the return electrode;wherein the active electrode defines a peripheral edge surface;wherein the insulative spacer body defines an aspiration cavity fluidly connected with an aspiration lumen and terminating with a cavity aperture having a perimeter, wherein the active electrode partially cover the cavity aperture so as to define at least one aspiration aperture having an aspiration aperture perimeter that is defined by the cavity aperture perimeter and the active electrode peripheral edge surface.
  • 2. The electrosurgical wand of claim 1 wherein the peripheral edge surface defines at least one active electrode lateral edge surface portion free of any asperities and spaced away from the cavity aperture.
  • 3. The electrosurgical wand of claim 1 wherein the active electrode further comprises an electrode aperture in fluid communication with the aspiration cavity and spaced away from the active electrode peripheral edge surface.
  • 4. The electrosurgical wand of claim 1, wherein the at least one aspiration aperture comprises at least two aspiration apertures each having a perimeter defined by the active electrode peripheral edge surface and the cavity aperture perimeter.
  • 5. The electrosurgical wand of claim 4 wherein the at least two aspiration apertures comprise a first and second aspiration aperture, the first aspiration aperture smaller than the second aspiration aperture.
  • 6. The electrosurgical wand of claim 5 wherein the first aspiration aperture has a perimeter defined by a portion of the peripheral edge surface having at least one internal cusp with a first depth and the second aspiration aperture has a perimeter defined by a portion of the peripheral edge surface having at least one internal cusp with a second depth and wherein the first cusp depth is significantly smaller than the second cusp depth and wherein the cusps are configured to create an internal point of higher current density and preferential vapor layer formation.
  • 7. The electrosurgical wand of claim 1 wherein the peripheral edge surface further comprises at least one internal cusp, configured to create a point of high current density for preferential vapor layer formation.
  • 8. The electrosurgical wand of claim 7 wherein the at least one internal cusp is defined by an intersection between two adjacent curved portions, the intersection characterized by an internal pointed feature.
  • 9. The electrosurgical wand of claim 1 further comprising at least one securing wire of conductive material, electrically coupled to and mechanically secured to a tissue contacting surface of the active electrode and wherein the at least one securing wire is disposed along a path defined by at least one active electrode wire aperture, at least one spacer body wire conduit and the elongate shaft and wherein the at least one securing wire is in electrical communication with a high frequency energy source.
  • 10. The electrosurgical wand of claim 1 wherein the aspiration cavity is characterized by an elongate funnel shape so that the cavity aperture defines a first dimension and second dimension that is less than the first dimension.
  • 11. The electrosurgical wand of claim 10 wherein the aspiration cavity tapers so as to define a maximum gap within the aspiration cavity, the gap configured so as to trap any larger tissue fragments within the aspiration cavity so that the tissue fragments are further ablated by a portion of the active electrode before allowing the fragments to pass into the aspiration lumen.
  • 12. The electrosurgical wand of claim 1 wherein the aspiration cavity has a tapered surface.
  • 13. An electrosurgical wand for treating tissue at a target site within or on a patient's body comprising: an elongate shaft having a handle end and a distal end portion, the distal end portion comprising an active electrode, an insulative spacer body and a return electrode, wherein the active electrode is disposed on a first surface of the insulative spacer body and is spaced away from the return electrode;wherein the active electrode comprises an outer edge surface defining first and second lateral and medial edge surface portions;wherein the insulative spacer body defines an aspiration cavity fluidly connected with an aspiration lumen and at least one aspiration aperture, the at least one aspiration aperture having a perimeter at least partially defined by at least one of the medial edge surface portions.
  • 14. The electrosurgical wand of claim 13, the at least one aspiration aperture comprising a first and second aspiration aperture, the first aspiration aperture having a perimeter at least partially defined by the first medial edge portion and the second aspiration aperture having a perimeter at least partially defined by the second medial edge surface portion.
  • 15. The electrosurgical wand of claim 14 wherein the first and second medial edge surface portions of the active electrode each further comprise at least one internal cusp, wherein at least one internal cusp is configured so as to create a preferential point of vapor layer formation, and wherein the at least one internal cusp is disposed along at least one of the first and second aspiration aperture perimeters.
  • 16. The electrosurgical wand of claim 14 wherein the first aspiration aperture extends a first distance beyond the first medial edge surface portion and the second aspiration aperture extends a second distance beyond the second medial edge surface portion of the active electrode and wherein the first distance is smaller than the second distance.
  • 17. The electrosurgical wand of claim 14 wherein the first medial edge surface portion of the active electrode has at least one internal cusp with a first depth and the second medial edge surface portion of the active electrode has at least one internal cusp with a second depth and wherein the first cusp depth is significantly smaller than the second cusp depth.
  • 18. The electrosurgical wand of claim 13 wherein the aspiration cavity is characterized by an elongate funnel shape.
  • 19. An electrosurgical wand for treating tissue at a target site within or on a patient's body comprising: an elongate shaft defining a handle end and a distal end portion, the distal end portion comprising an active electrode, an insulative spacer body and a return electrode, wherein the active electrode is disposed on a distal surface of the insulative spacer body and is spaced away from the return electrode;wherein the active electrode defines a peripheral edge surface defining distal and proximal edge surfaces;wherein the insulative spacer body defines an aspiration cavity fluidly connected with an aspiration lumen and configured to aspirate fluid and plasma by-products therethrough, the aspiration cavity terminating on the distal surface of the spacer body with at least one cavity aperture, and wherein the active electrode covers a portion of the cavity aperture so as to define at least one aspiration aperture, the at least one aspiration aperture having a perimeter lying on a plane defined by the spacer body distal surface and defined by the active electrode peripheral edge surface and a perimeter of the cavity aperture.
  • 20. The electrosurgical wand for treating tissue of claim 19 wherein the distal edge surface further comprises at least one internal cusp and wherein the aspiration aperture perimeter is further defined by the distal edge surface and the at least one internal cusp.
  • 21. The electrosurgical wand for treating tissue of claim 19 wherein the proximal edge surface further comprises at least one internal cusp and wherein the aspiration aperture perimeter is further defined by the proximal edge surface and the at least one internal cusp.
  • 22. The electrosurgical wand for treating tissue of claim 19 wherein the aspiration aperture perimeter is further defined by a portion of the active electrode peripheral edge surface that is shaped with an edge surface geometry that elongates a perimeter of the peripheral edge surface, configured to enhance vapor layer formation along the peripheral edge.
US Referenced Citations (523)
Number Name Date Kind
2050904 Trice Aug 1936 A
2056377 Wappler Oct 1939 A
2275167 Bierman Mar 1942 A
3633425 Sanford Jan 1972 A
3699967 Anderson Oct 1972 A
3812858 Oringer May 1974 A
3815604 O'Malley et al. Jun 1974 A
3828780 Morrison, Jr. et al. Aug 1974 A
3901242 Storz Aug 1975 A
3920021 Hiltebrandt Nov 1975 A
3939839 Curtiss Feb 1976 A
3945375 Banko Mar 1976 A
3970088 Morrison Jul 1976 A
4033351 Hetzel Jul 1977 A
4040426 Morrison, Jr. Aug 1977 A
4043342 Morrison, Jr. Aug 1977 A
4074718 Morrison, Jr. Feb 1978 A
4092986 Schneiderman Jun 1978 A
4116198 Roos Sep 1978 A
4181131 Ogiu Jan 1980 A
4184492 Meinke et al. Jan 1980 A
4202337 Hren et al. May 1980 A
4203444 Bonnell et al. May 1980 A
4228800 Degler, Jr. et al. Oct 1980 A
4232676 Herczog Nov 1980 A
4240441 Khalil Dec 1980 A
4248231 Herczog et al. Feb 1981 A
4269174 Adair May 1981 A
4326529 Doss et al. Apr 1982 A
4381007 Doss Apr 1983 A
4411266 Cosman Oct 1983 A
4429694 McGreevy Feb 1984 A
4474179 Koch Oct 1984 A
4476862 Pao Oct 1984 A
4483338 Bloom et al. Nov 1984 A
4532924 Auth et al. Aug 1985 A
4548207 Reimels Oct 1985 A
4567890 Ohta et al. Feb 1986 A
4582057 Auth et al. Apr 1986 A
4590934 Malis et al. May 1986 A
4593691 Lindstrom et al. Jun 1986 A
4641649 Walinsky Feb 1987 A
4658817 Hardy Apr 1987 A
4660571 Hess et al. Apr 1987 A
4674499 Pao Jun 1987 A
4682596 Bales et al. Jul 1987 A
4706667 Roos Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4727874 Bowers et al. Mar 1988 A
4736743 Daikuzono Apr 1988 A
4737678 Hasegawa Apr 1988 A
4762128 Rosenbluth Aug 1988 A
4765331 Petruzzi et al. Aug 1988 A
4785806 Deckelbaum Nov 1988 A
4785823 Eggers et al. Nov 1988 A
4805616 Pao Feb 1989 A
4813429 Eshel et al. Mar 1989 A
4823791 D'Amelio et al. Apr 1989 A
4827911 Broadwin et al. May 1989 A
4832048 Cohen May 1989 A
4860752 Turner et al. Aug 1989 A
4903696 Stasz et al. Feb 1990 A
4907589 Cosman Mar 1990 A
4920978 Colvin May 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4936301 Rexroth et al. Jun 1990 A
4940064 Desai Jul 1990 A
4943290 Rexroth et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4966597 Cosman Oct 1990 A
4967765 Turner et al. Nov 1990 A
4968314 Michaels Nov 1990 A
4976709 Sand Dec 1990 A
4976711 Parins et al. Dec 1990 A
4979948 Geddes et al. Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5007437 Sterzer Apr 1991 A
5007908 Rydell Apr 1991 A
5009656 Reimels Apr 1991 A
5035696 Rydell Jul 1991 A
5037421 Boutacoff et al. Aug 1991 A
5047026 Rydell Sep 1991 A
5047027 Rydell Sep 1991 A
5057105 Malone et al. Oct 1991 A
5057106 Kasevich et al. Oct 1991 A
5061266 Hakky Oct 1991 A
5078717 Parins et al. Jan 1992 A
5080660 Buelna Jan 1992 A
5083565 Parins Jan 1992 A
5084044 Quint Jan 1992 A
5085659 Rydell Feb 1992 A
5088997 Delahuerga et al. Feb 1992 A
5092339 Geddes et al. Mar 1992 A
5093877 Aita et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5099840 Goble Mar 1992 A
5102410 Dressel Apr 1992 A
5103804 Abele et al. Apr 1992 A
5108391 Flachenecker et al. Apr 1992 A
RE33925 Bales et al. May 1992 E
5112330 Nishigaki et al. May 1992 A
5122138 Manwaring Jun 1992 A
5125928 Parins et al. Jun 1992 A
5137530 Sand Aug 1992 A
5147354 Boutacoff et al. Sep 1992 A
5151098 Loertscher Sep 1992 A
5156151 Imran Oct 1992 A
5167659 Ohtomo et al. Dec 1992 A
5171311 Rydell et al. Dec 1992 A
5176528 Fry et al. Jan 1993 A
5178620 Eggers et al. Jan 1993 A
5190517 Zieve et al. Mar 1993 A
5191883 Lennox et al. Mar 1993 A
5192280 Parins Mar 1993 A
5195959 Smith Mar 1993 A
5197466 Marchosky et al. Mar 1993 A
5197963 Parins Mar 1993 A
5207675 Canady May 1993 A
5217455 Tan Jun 1993 A
5217457 Delahuerga et al. Jun 1993 A
5217459 Kamerling Jun 1993 A
5230334 Klopotek Jul 1993 A
5234428 Kaufman Aug 1993 A
5246438 Langberg Sep 1993 A
5249585 Turner et al. Oct 1993 A
5261410 Alfano et al. Nov 1993 A
5267994 Gentelia et al. Dec 1993 A
5267997 Farin et al. Dec 1993 A
5269794 Rexroth Dec 1993 A
5273524 Fox et al. Dec 1993 A
5277201 Stern Jan 1994 A
5277696 Hagen Jan 1994 A
5279299 Imran Jan 1994 A
5281216 Klicek Jan 1994 A
5281218 Imran Jan 1994 A
5282797 Chess Feb 1994 A
5282799 Rydell Feb 1994 A
5290273 Tan Mar 1994 A
5290282 Casscells Mar 1994 A
5293868 Nardella Mar 1994 A
5300069 Hunsberger et al. Apr 1994 A
5300099 Rudie Apr 1994 A
5301687 Wong et al. Apr 1994 A
5304169 Sand Apr 1994 A
5304170 Green Apr 1994 A
5306238 Fleenor Apr 1994 A
5312395 Tan et al. May 1994 A
5312400 Bales et al. May 1994 A
5314406 Arias et al. May 1994 A
5318563 Malis et al. Jun 1994 A
5322507 Costello et al. Jun 1994 A
5324254 Phillips Jun 1994 A
5330470 Hagen Jul 1994 A
5330518 Neilson et al. Jul 1994 A
5334140 Phillips Aug 1994 A
5334183 Wuchinich Aug 1994 A
5334193 Nardella Aug 1994 A
5335668 Nardella Aug 1994 A
5336217 Buys et al. Aug 1994 A
5336220 Ryan et al. Aug 1994 A
5336443 Odashima Aug 1994 A
5342357 Nardella Aug 1994 A
5348554 Imran et al. Sep 1994 A
5366443 Eggers et al. Nov 1994 A
5370642 Keller Dec 1994 A
5370644 Langberg Dec 1994 A
5370675 Edwards et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5374265 Sand Dec 1994 A
5375588 Yoon Dec 1994 A
5380277 Phillips Jan 1995 A
5380316 Aita et al. Jan 1995 A
5383876 Nardella Jan 1995 A
5383917 Desai et al. Jan 1995 A
5389096 Aita Feb 1995 A
5395312 Desai Mar 1995 A
5395363 Billings et al. Mar 1995 A
5400267 Denen et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5417687 Nardella et al. May 1995 A
5419767 Eggers et al. May 1995 A
5423803 Tankovich Jun 1995 A
5423810 Goble et al. Jun 1995 A
5423844 Miller Jun 1995 A
5423882 Jackman et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5436566 Thompson et al. Jul 1995 A
5437662 Nardella Aug 1995 A
5437664 Cohen et al. Aug 1995 A
5438302 Goble Aug 1995 A
5441499 Fritzsch Aug 1995 A
5445634 Keller Aug 1995 A
5451224 Goble et al. Sep 1995 A
5454809 Janssen Oct 1995 A
5458596 Lax et al. Oct 1995 A
5462545 Wang et al. Oct 1995 A
5484435 Fleenor et al. Jan 1996 A
5487385 Avitall Jan 1996 A
5490850 Ellman et al. Feb 1996 A
5496312 Klicek Mar 1996 A
5496314 Eggers Mar 1996 A
5496317 Goble et al. Mar 1996 A
5514130 Baker May 1996 A
5520685 Wojciechowicz May 1996 A
5536267 Edwards et al. Jul 1996 A
5542928 Evans et al. Aug 1996 A
5545161 Imran Aug 1996 A
5554152 Aita Sep 1996 A
5556397 Long et al. Sep 1996 A
5562703 Desai Oct 1996 A
5569242 Lax et al. Oct 1996 A
5571100 Goble et al. Nov 1996 A
5579764 Goldreyer Dec 1996 A
5584872 LaFontaine et al. Dec 1996 A
5607421 Jeevanandam et al. Mar 1997 A
5609151 Mulier et al. Mar 1997 A
5626576 Janssen May 1997 A
5633578 Eggers et al. May 1997 A
5643255 Organ Jul 1997 A
5647869 Goble et al. Jul 1997 A
5660836 Knowlton Aug 1997 A
5662680 Desai Sep 1997 A
5676693 LaFontaine et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5700262 Acosta et al. Dec 1997 A
5713896 Nardella Feb 1998 A
5725524 Mulier et al. Mar 1998 A
5743870 Edwards Apr 1998 A
5743903 Stern et al. Apr 1998 A
5746746 Garito et al. May 1998 A
5749869 Lindenmeier et al. May 1998 A
5755753 Knowlton May 1998 A
5766153 Eggers et al. Jun 1998 A
5769843 Abela et al. Jun 1998 A
5769847 Panescu et al. Jun 1998 A
5782795 Bays Jul 1998 A
5785705 Baker Jul 1998 A
5800429 Edwards Sep 1998 A
5800431 Brown Sep 1998 A
5807384 Mueller Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5810809 Rydell Sep 1998 A
5836875 Webster, Jr. Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5843078 Sharkey Dec 1998 A
5855277 Apps et al. Jan 1999 A
5860951 Eggers Jan 1999 A
5860974 Abele Jan 1999 A
5860975 Goble et al. Jan 1999 A
5871469 Eggers et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5876398 Mulier et al. Mar 1999 A
5885277 Korth Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5891134 Goble et al. Apr 1999 A
5893848 Negus et al. Apr 1999 A
5895386 Odell et al. Apr 1999 A
5897553 Mulier Apr 1999 A
5902272 Eggers et al. May 1999 A
5904681 West, Jr. May 1999 A
5906613 Mulier et al. May 1999 A
5919219 Knowlton Jul 1999 A
5944715 Goble et al. Aug 1999 A
5954716 Sharkey et al. Sep 1999 A
5964754 Osypka Oct 1999 A
5976127 Lax Nov 1999 A
5980516 Mulier et al. Nov 1999 A
5980545 Pacala et al. Nov 1999 A
5984919 Hilal et al. Nov 1999 A
6004319 Goble et al. Dec 1999 A
6007533 Casscells et al. Dec 1999 A
6013076 Goble et al. Jan 2000 A
6015406 Goble et al. Jan 2000 A
6016809 Mulier et al. Jan 2000 A
6024733 Eggers et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6030383 Benderev Feb 2000 A
6032673 Savage et al. Mar 2000 A
6032674 Eggers et al. Mar 2000 A
6039734 Goble et al. Mar 2000 A
6045532 Eggers et al. Apr 2000 A
6047700 Eggers et al. Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6056746 Goble et al. May 2000 A
6063079 Hovda et al. May 2000 A
6063081 Mulier et al. May 2000 A
6066134 Eggers et al. May 2000 A
6068628 Fanton et al. May 2000 A
6074386 Goble et al. Jun 2000 A
6090106 Goble et al. Jul 2000 A
6091995 Ingle et al. Jul 2000 A
6093186 Goble et al. Jul 2000 A
6096037 Mulier et al. Aug 2000 A
6102046 Weinstein et al. Aug 2000 A
6105581 Eggers et al. Aug 2000 A
6109268 Thapliyal et al. Aug 2000 A
6110169 Mueller et al. Aug 2000 A
6117109 Eggers et al. Sep 2000 A
6126682 Sharkey et al. Oct 2000 A
6142992 Cheng et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6152923 Ryan Nov 2000 A
6156031 Aita et al. Dec 2000 A
6159194 Eggers et al. Dec 2000 A
6159208 Hovda et al. Dec 2000 A
6168593 Sharkey et al. Jan 2001 B1
6174309 Wrublewski et al. Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6179836 Eggers et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6190381 Olsen et al. Feb 2001 B1
6203542 Ellsberry et al. Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6210405 Goble et al. Apr 2001 B1
6214001 Casscells et al. Apr 2001 B1
6217575 DeVore et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6228078 Eggers May 2001 B1
6228081 Goble May 2001 B1
6234178 Goble et al. May 2001 B1
6235020 Cheng et al. May 2001 B1
6237604 Burnside et al. May 2001 B1
6238391 Olsen et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6254600 Willink Jul 2001 B1
6261286 Goble et al. Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264650 Hovda Jul 2001 B1
6264652 Eggers et al. Jul 2001 B1
6267757 Aita et al. Jul 2001 B1
6270460 McCartan et al. Aug 2001 B1
6277112 Underwood et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6283961 Underwood et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6302903 Mulier et al. Oct 2001 B1
6306134 Goble et al. Oct 2001 B1
6308089 von der Ruhr et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6312429 Burbank et al. Nov 2001 B1
6315774 Daniel et al. Nov 2001 B1
6322494 Bullivant et al. Nov 2001 B1
6322549 Eggers et al. Nov 2001 B1
6325799 Goble Dec 2001 B1
6327505 Medhkour et al. Dec 2001 B1
6328736 Mulier et al. Dec 2001 B1
6336926 Goble Jan 2002 B1
6346107 Cucin Feb 2002 B1
6355006 Ryaby et al. Mar 2002 B1
6355032 Hovda et al. Mar 2002 B1
6358248 Mulier et al. Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6364877 Goble et al. Apr 2002 B1
6379350 Sharkley et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6391025 Weinstein et al. May 2002 B1
6391028 Fanton et al. May 2002 B1
6398781 Goble et al. Jun 2002 B1
6409724 Penny et al. Jun 2002 B1
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6416509 Goble et al. Jul 2002 B1
6432103 Ellsberry et al. Aug 2002 B1
6432105 Ellman et al. Aug 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6468275 Wampler et al. Oct 2002 B1
6482201 Olsen et al. Nov 2002 B1
6482202 Goble et al. Nov 2002 B1
6491690 Gobel et al. Dec 2002 B1
6510854 Gobel Jan 2003 B2
6514250 Jahns et al. Feb 2003 B1
6517498 Burbank et al. Feb 2003 B1
6517535 Edwards Feb 2003 B2
6530922 Cosman Mar 2003 B2
6540741 Underwood et al. Apr 2003 B1
6557559 Eggers et al. May 2003 B1
6575968 Eggers et al. Jun 2003 B1
6575969 Rittman, III et al. Jun 2003 B1
6578579 Burnside Jun 2003 B2
6582423 Thapliyal et al. Jun 2003 B1
6589237 Woloszko et al. Jul 2003 B2
6595990 Weinstein et al. Jul 2003 B1
6602248 Sharps et al. Aug 2003 B1
6610059 West, Jr. Aug 2003 B1
6620156 Garito et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6632230 Barry Oct 2003 B2
6663628 Peters Dec 2003 B2
6699206 Burbank et al. Mar 2004 B2
6746447 Davison et al. Jun 2004 B2
6749604 Eggers et al. Jun 2004 B1
6749608 Garito et al. Jun 2004 B2
6763836 Tasto et al. Jul 2004 B2
6770071 Woloszko et al. Aug 2004 B2
6780178 Palanker et al. Aug 2004 B2
6780180 Goble et al. Aug 2004 B1
6802842 Ellman et al. Oct 2004 B2
6805130 Tasto et al. Oct 2004 B2
6832996 Woloszko et al. Dec 2004 B2
6837887 Woloszko et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6855143 Davison et al. Feb 2005 B2
6896674 Woloszko et al. May 2005 B1
6904303 Phan et al. Jun 2005 B2
6920883 Bessette et al. Jul 2005 B2
6929640 Underwood et al. Aug 2005 B1
6949096 Davison et al. Sep 2005 B2
6960204 Eggers et al. Nov 2005 B2
6974453 Woloszko et al. Dec 2005 B2
6979332 Adams Dec 2005 B2
6984231 Goble et al. Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
7004941 Tvinnereim et al. Feb 2006 B2
7041102 Truckai et al. May 2006 B2
7070596 Woloszko et al. Jul 2006 B1
7090672 Underwood et al. Aug 2006 B2
7094215 Davison et al. Aug 2006 B2
7104986 Hovda et al. Sep 2006 B2
7131969 Hovda et al. Nov 2006 B1
7150746 DeCesare Dec 2006 B2
7169143 Eggers et al. Jan 2007 B2
7179255 Lettice et al. Feb 2007 B2
7184811 Phan et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7192428 Eggers et al. Mar 2007 B2
7201750 Eggers et al. Apr 2007 B1
7217268 Eggers et al. May 2007 B2
7241293 Davison Jul 2007 B2
7261712 Burbank et al. Aug 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7270659 Hovda et al. Sep 2007 B2
7270661 Dahla et al. Sep 2007 B2
7276063 Davison et al. Oct 2007 B2
7297143 Woloszko et al. Nov 2007 B2
7297145 Ormsby et al. Nov 2007 B2
7318823 Sharps et al. Jan 2008 B2
7331956 Hovda et al. Feb 2008 B2
RE40156 Sharps et al. Mar 2008 E
7357798 Sharps et al. Apr 2008 B2
7387625 Hovda et al. Jun 2008 B2
7419488 Ciarrocca et al. Sep 2008 B2
7429260 Underwood et al. Sep 2008 B2
7429262 Woloszko et al. Sep 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7442191 Hovda et al. Oct 2008 B2
7445618 Eggers et al. Nov 2008 B2
7449021 Underwood et al. Nov 2008 B2
7462178 Woloszko et al. Dec 2008 B2
7468059 Eggers et al. Dec 2008 B2
7488295 Burbank et al. Feb 2009 B2
7491200 Underwood et al. Feb 2009 B2
7507236 Eggers et al. Mar 2009 B2
7566333 Van Wyk Jul 2009 B2
7572251 Davison et al. Aug 2009 B1
7632267 Dahla Dec 2009 B2
7691101 Davison et al. Apr 2010 B2
7704249 Woloszko et al. Apr 2010 B2
7708733 Sanders et al. May 2010 B2
20020029036 Goble et al. Mar 2002 A1
20020049438 Sharkey et al. Apr 2002 A1
20020072739 Lee et al. Jun 2002 A1
20030013986 Saadat Jan 2003 A1
20030088245 Woloszko et al. May 2003 A1
20030097129 Davison May 2003 A1
20030130655 Woloszko et al. Jul 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030171743 Tasto et al. Sep 2003 A1
20030208196 Stone Nov 2003 A1
20030212396 Eggers et al. Nov 2003 A1
20030225403 Woloszko Dec 2003 A1
20040116922 Hovda et al. Jun 2004 A1
20040127893 Hovda Jul 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20050004634 Hovda et al. Jan 2005 A1
20050261754 Woloszko et al. Nov 2005 A1
20050288665 Woloszko et al. Dec 2005 A1
20060036237 Davison et al. Feb 2006 A1
20060095031 Ormsby May 2006 A1
20060178670 Woloszko et al. Aug 2006 A1
20060189971 Eggers et al. Aug 2006 A1
20060253117 Hovda et al. Nov 2006 A1
20060259025 Dahla Nov 2006 A1
20070106288 Woloszko et al. May 2007 A1
20070149966 Dahla et al. Jun 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070208334 Woloszko et al. Sep 2007 A1
20070208335 Woloszko et al. Sep 2007 A1
20070282323 Woloszko et al. Dec 2007 A1
20080021447 Davison et al. Jan 2008 A1
20080167646 Godara et al. Jul 2008 A1
20080234673 Marion et al. Sep 2008 A1
20090069807 Eggers et al. Mar 2009 A1
20090209958 Davison et al. Aug 2009 A1
20100042095 Bigley et al. Feb 2010 A1
20100152724 Marion et al. Jun 2010 A1
20100204690 Bigley Aug 2010 A1
20110270242 Marion Nov 2011 A1
20120083782 Stalder Apr 2012 A1
20130197506 Evans Aug 2013 A1
20140200581 Aluru Jul 2014 A1
20140257269 Woloszko Sep 2014 A1
20140336630 Woloszko Nov 2014 A1
20150245862 Goode Sep 2015 A1
20160022350 Yuan Jan 2016 A1
Foreign Referenced Citations (102)
Number Date Country
2521719 Nov 1976 DE
3930451 Mar 1991 DE
4425015 Jan 1996 DE
296 09 350 Aug 1996 DE
195 37 084 Apr 1997 DE
296 19 029 Apr 1997 DE
102009057921 Jun 2010 DE
0 502 268 Sep 1992 EP
0 515 867 Dec 1992 EP
0 597 463 May 1994 EP
774926 Mar 1995 EP
0 650 701 May 1995 EP
0703461 Mar 1996 EP
0740926 Nov 1996 EP
0754437 Jan 1997 EP
923907 Jun 1999 EP
0694290 Nov 2000 EP
1149564 Oct 2001 EP
2313949 Jan 1977 FR
2037167 Jul 1980 GB
2 308 979 Jul 1997 GB
2 308 980 Jul 1997 GB
2 308 981 Jul 1997 GB
2 327 350 Jan 1999 GB
2 327 351 Jan 1999 GB
2 327 352 Jan 1999 GB
2331247 May 1999 GB
2379878 Mar 2003 GB
2408936 Jun 2005 GB
57-57802 Apr 1982 JP
57-117843 Jul 1982 JP
57-183850 Nov 1982 JP
63-40099 Aug 1988 JP
9-501328 Feb 1997 JP
9003152 Apr 1990 WO
9007303 Jul 1990 WO
9113650 Sep 1991 WO
9221278 Dec 1992 WO
9313816 Jul 1993 WO
9320747 Oct 1993 WO
9403134 Feb 1994 WO
9404220 Mar 1994 WO
9408654 Apr 1994 WO
9410924 May 1994 WO
9414383 Jul 1994 WO
9426228 Nov 1994 WO
9505780 Mar 1995 WO
9505781 Mar 1995 WO
9505867 Mar 1995 WO
9510326 Apr 1995 WO
9530373 Nov 1995 WO
9534259 Dec 1995 WO
9600042 Jan 1996 WO
9607360 Mar 1996 WO
9634568 Nov 1996 WO
9635469 Nov 1996 WO
9639914 Dec 1996 WO
9639962 Dec 1996 WO
9639964 Dec 1996 WO
9639965 Dec 1996 WO
9639967 Dec 1996 WO
9700646 Jan 1997 WO
9700647 Jan 1997 WO
9715238 May 1997 WO
9718765 May 1997 WO
9724073 Jul 1997 WO
9724074 Jul 1997 WO
9724992 Jul 1997 WO
9724993 Jul 1997 WO
9724994 Jul 1997 WO
9725101 Jul 1997 WO
9732551 Sep 1997 WO
9734540 Sep 1997 WO
9741786 Nov 1997 WO
9744071 Nov 1997 WO
9748345 Dec 1997 WO
9748346 Dec 1997 WO
9807468 Feb 1998 WO
9814131 Apr 1998 WO
9817185 Apr 1998 WO
9817186 Apr 1998 WO
9827877 Jul 1998 WO
9827879 Jul 1998 WO
9827880 Jul 1998 WO
9830144 Jul 1998 WO
9834558 Aug 1998 WO
9838925 Sep 1998 WO
9839038 Sep 1998 WO
9900060 Jan 1999 WO
9920185 Apr 1999 WO
9942037 Aug 1999 WO
9944506 Sep 1999 WO
9951155 Oct 1999 WO
9951158 Oct 1999 WO
0009053 Feb 2000 WO
0126570 Apr 2001 WO
0187154 May 2001 WO
0195819 Dec 2001 WO
0236028 May 2002 WO
02078557 Oct 2002 WO
03024339 Mar 2003 WO
2005125287 Dec 2005 WO
Non-Patent Literature Citations (107)
Entry
Barry et al., “The Effect of Radiofrequency-generated Thermal Energy on the Mechanical and Histologic Characteristics of the Arterial Wall in Vivo: Implications of Radiofrequency Angioplasty” American Heart Journal vol. 117, pp. 332-341, 1982.
BiLAP Generator Settings, Jun. 1991.
BiLAP IFU 910026-001 Rev A for BiLAP Model 3525, J-Hook, 4 pgs, May 20, 1991.
BiLAP IFU 910033-002 Rev A for BiLAP Model 3527, L-Hook; BiLAP Model 3525, J-Hook; BiLAP Model 3529, High Angle, 2 pgs, Nov. 30, 1993.
Codman & Shurtleff, Inc. “The Malis Bipolar Coagulating and Bipolar Cutting System CMC-II” brochure, early, 2 pgs, 1991.
Codman & Shurtleff, Inc. “The Malis Bipolar Electrosurgical System CMC-III Instruction Manual”, 15 pgs, Jul. 1991.
Cook et al., “Therapeutic Medical Devices: Application and Design”, Prentice Hall, Inc., 3pgs, 1982.
Dennis et al. “Evolution of Electrofulguration in Control of Bleeding of Experimental Gastric Ulcers,” Digestive Diseases and Sciences, vol. 24, No. 11, 845-848, Nov. 1979.
Dobbie, A.K., “The Electrical Aspects of Surgical Diathermy, Bio Medical Engineering” Bio-Medical Engineering vol. 4, pp. 206-216, May 1969.
Elsasser, V.E. et al., “An Instrument for Transurethral Resection without Leakage of Current” Acta Medicotechnica vol. 24, No. 4, pp. 129-134, 1976.
Geddes, “Medical Device Accidents: With Illustrative Cases” CRC Press, 3 pgs, 1998.
Honig, W., “The Mechanism of Cutting in Electrosurgery” IEEE pp. 58-65, 1975.
Kramolowsky et al. “The Urological App of Electorsurgery” J. of Urology vol. 146, pp. 669-674, 1991.
Kramolowsky et al. “Use of 5F Bipolar Electrosurgical Probe in Endoscopic Urological Procedures” J. of Urology vol. 143, pp. 275-277, 1990.
Lee, B et al. “Thermal Compression and Molding of Artherosclerotic Vascular Tissue with Use” JACC vol. 13(5), pp. 1167-1171, 1989.
Letter from Department of Health to Jerry Malis dated Jan. 24, 1991, 3 pgs.
Letter from Department of Health to Jerry Malis dated Jul. 25, 1985, 1 pg.
Letter from Jerry Malis to FDA dated Jul. 25, 1985, 2 pgs.
Lu, et al., “Electrical Thermal Angioplasty: Catheter Design Features, In Vitro Tissue Ablation Studies and In Vitro Experimental Findings,” Am J. Cardiol vol. 60, pp. 1117-1122, Nov. 1, 1987.
Malis, L., “Electrosurgery, Technical Note,” J. Neursurg., vol. 85, pp. 970-975, Nov. 1996.
Malis, L., “Excerpted from a seminar by Leonard I. Malis, M.D. at the 1995 American Association of Neurological Surgeons Meeting,” 1pg, 1995.
Malis, L., “Instrumentation for Microvascular Neurosurgery” Cerebrovascular Surgery, vol. 1, pp. 245-260, 1985.
Malis, L., “New Trends in Microsurgery and Applied Technology,” Advanced Technology in Neurosurgery, pp. 1-16, 1988.
Malis, L., “The Value of Irrigation During Bipolar Coagulation” See ARTC 21602, 1 pg, Apr. 9, 1993.
Nardella, P.C., SPIE 1068: pp. 42-49, Radio Frequency Energy and Impedance Feedback, 1989.
O'Malley, Schaum's Outline of Theory and Problems of Basic Circuit Analysis, McGraw-Hill, 2nd Ed., pp. 3-5, 1992.
Olsen MD, Bipolar Laparoscopic Cholecstectomy Lecture (marked confidential), 12 pgs, Oct. 7, 1991.
Pearce, John A. “Electrosurgery”, pp. 17, 69-75, 87, John Wiley & Sons, New York, 1986.
Pearce, John A., “Electrosurgery”, Handbook of Biomedical Engineering, chapter 3, Academic Press Inc., N.Y., pp. 98-113, 1988.
Piercey et al., “Electrosurgical Treatment of Experimental Bleeding Canine Gastric Ulcers” Gastroenterology vol. 74(3), pp. 527-534, 1978.
Protell et al., “Computer-Assisted Electrocoagulation: Bipolar v. Monopolar in the Treatment of Experimental Canine Gastric Ulcer Bleeding,” Gastroenterology vol. 80, No. 3, pp. 451-455, 1981.
Ramsey et al., “A Comparison of Bipolar and Monopolar Diathermy Probes in Experimental Animals”, Urological Research vol. 13, pp. 99-102, 1985.
Selikowitz et al., “Electric Current and Voltage Recordings on the Myocardium During Electrosurgical Procedures in Canines,” Surgery, Gynecology & Obstetrics, vol. 164, pp. 219-224, Mar. 1987.
Shuman, Bipolar Versus Monopolar Electrosurgery: Clinical Applications, Dentistry Today, vol. 20, No. 12, 7 pgs, Dec. 2001.
Slager et al. “Spark Erosion of Arteriosclerotic Plaques” Z. Kardiol. 76:Suppl. 6, pp. 67-71, 1987.
Slager et al. “Vaporization of Atherosclerotice Plaques by Spark Erosion” JACC 5(6): pp. 1382-1386, Jun. 1985.
Stoffels, E. et al., “Investigation on the Interaction Plasma-Bone Tissue”, E-MRS Spring Meeting, 1 pg, Jun. 18-21, 2002.
Stoffels, E. et al., “Biomedical Applications of Plasmas”, Tutorial presented prior to the 55th Gaseous Electronics Conference in Minneapolis, MN, 41 pgs, Oct. 14, 2002.
Stoffels, E. et al., “Plasma Interactions with Living Cells”, Eindhoven University of Technology, 1 pg, 2002.
Stoffels, E. et al., “Superficial Treatment of Mammalian Cells using Plasma Needle”, J. Phys. D: Appl. Phys. 26, pp. 2908-2913, Nov. 19, 2003.
Stoffels, E. et al., “Plasma Needle”, Eindhoven University of Technology, 1 pg, Nov. 28, 2003.
Stoffels, E. et al., “Plasma Physicists Move into Medicine”, Physicsweb, 1 pg, Nov. 2003.
Stoffels, E. et al., “Plasma Treated Tissue Engineered Skin to Study Skin Damage”, Biomechanics and Tissue Engineering, Materials Technology, 1 pg, 2003.
Stoffels, E. et al., “Plasma Treatment of Dental Cavities: A Feasibility Study”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1540-1542, Aug. 2004.
Stoffels, E. et al., “The Effects of UV Irradiation and Gas Plasma Treatment on Living Mammalian Cells and Bacteria: A Comparative Approach”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1544-1550, Aug. 2004.
Stoffels, E. et al., “Electrical and Optical Characterization of the Plasma Needle”, New Journal of Physics 6, pp. 1-14, Oct. 28, 2004.
Stoffels, E. et al., “Where Plasma Meets Plasma”, Eindhoven University of Technology, 23 pgs, 2004.
Stoffels, E. et al., “Gas Plasma effects on Living Cells”, Physica Scripta, T107, pp. 79-82, 2004.
Stoffels, E. et al., “Plasma Treatment of Mammalian Vascular Cells: A Quantitative Description”, IEEE Transaction on Plasma Science, vol. 33, No. 2, pp. 771-775, Apr. 2005.
Stoffels, E. et al., “Deactivation of Escherichia coli by the Plasma Needle”, J. Phys. D: Appl. Phys. 38, pp. 1716-1721, May 20, 2005.
Stoffels, E. et al., “Development of a Gas Plasma Catheter for Gas Plasma Surgery”, XXVIIth ICPIG, Endoven University of Technology, pp. 18-22, Jul. 2005.
Stoffels, E. et al., “Development of a Smart Positioning Sensor for the Plasma Needle”, Plasma Sources Sci. Technol. 15, pp. 582-589, Jun. 27, 2006.
Stoffels, E. et al., Killing of S. mutans bacteria Using a Plasma Needle at Atmospheric Pressure, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1317-1324, Aug. 2006.
Stoffels, E. et al., “Plasma-Needle Treatment of Substrates with Respect to Wettability and Growth of Excherichia coli and Streptococcus mutans”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1325-1330, Aug. 2006.
Stoffels, E. et al., “Reattachment and Apoptosis after Plasma-Needle Treatment of Cultured Cells”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1331-1336, Aug. 2006.
Stoffels, E. et al., “UV Excimer Lamp Irradiation of Fibroblasts: The Influence on Antioxidant Homostasis”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1359-1364, Aug. 2006.
Stoffels, E. et al., “Plasma Needle for In Vivo Medical Treatment: Recent Developments and Perspectives”, Plasma Sources Sci. Technol. 15, pp. S169-S180, Oct. 6, 2006.
Swain, C.P., et al., “Which Electrode, A Comparison of four endoscopic methods of electrocoagulation in experimental bleeding ulcers” Gut vol. 25, pp. 1424-1431, 1987.
Tucker, R. et al., Abstract P14-11, p. 248, “A Bipolar Electrosurgical Turp Loop”, Nov. 1989.
Tucker, R. et al. “A Comparison of Urologic Application of Bipolar Versus Monopolar Five French Electrosurgical Probes” J. of Urology vol. 141, pp. 662-665, 1989.
Tucker, R. et al. “In vivo effect of 5 French Bipolar and Monopolar Electrosurgical Probes on the Porcine Bladder” Urological Research vol. 18, pp. 291-294, 1990.
Tucker, R. et al., “Demodulated Low Frequency Currents from Electrosurgical Procedures,” Surgery, Gynecology and Obstetrics, 159:39-43, 1984.
Tucker et al. “The interaction between electrosurgical generators, endoscopic electrodes, and tissue,” Gastrointestinal Endoscopy, vol. 38, No. 2, pp. 118-122, 1992.
Valley Forge Scientific Corp., “Summary of Safety and Effective Information from 510K”, 2pgs, 1991.
Valley Forge's New Products, CLINICA, 475, 5, Nov. 6, 1991.
Valleylab SSE2L Instruction Manual, 11 pgs, Jan. 6, 1983.
Valleylab, Inc. “Valleylab Part No. 945 100 102 A” Surgistat Service Manual, pp. 1-46, Jul. 1988.
Wattiez, Arnaud et al., “Electrosurgery in Operative Endoscopy,” Electrosurgical Effects, Blackwell Science, pp. 85-93, 1995.
Wyeth, “Electrosurgical Unit” pp. 1181-1202, 2000.
Buchelt, et al. “Excimer Laser Ablation of Fibrocartilage: An In Vitro and In Vivo Study”, Lasers in Surgery and Medicine, vol. 11, pp. 271-279, 1991.
Costello et al., “Nd: YAG Laser Ablation of the Prostate as a Treatment for Benign Prostatic Hypertrophy”, Lasers in Surgery and Medicine, vol. 12, pp. 121-124, 1992.
Hardy et al., “Regional Myocardial Blood Flow and Cardiac mechanics in dog Hearts with CO2 laser-induced Intramyocardial Revascularization”, Basic Research in cardiology 85:179-196 (1990).
Mirhoseini et al., “New Concepts in Revascularization of the Myocardium”, Ann Thorac Surg 45:415-420 (1988).
Mirhoseini et al., “Revascularization of the heart by Laser”, J. of Microsurgery 2:253-260 (1981).
Mirhoseini et al., “Transmyocardial Laser Revascularization: A Review”, J. of Clinical Laser medicine & Surgery 11 (1) :15-19 (1993).
Mirhoseini et al., “Transventricular Revascularization by Laser”, Lasers in Surgery and Medicine 2:187-198 (1982).
Rand et al., “Effect of Elecctrocautery on Fresh Human Articular Cartilage”, J. Arthro. Surg., vol. 1, pp. 242-246, 1985.
Walter et al., “Treatment of Acute Mycardial Infarction by Transmural Blood Supply from the Ventricular Cavity”, Erop. Surgery Res. 3:130-138 (1971).
Whittaker et al., “Transmural Channels Can Protect Ischemic Tissue”, Circulation 93(1):143-152, Jan. 1, 1996.
EP Search Report for EP01124768 2 pgs, Nov. 30, 2001.
EP Search Report for EP01935650 10 pgs, Mailed Jul. 26, 2006.
EP Search Report for EP01935650 8 pgs, Mailed May 3, 2005.
EP Search Report for EP02768969 3 pgs, Mailed Feb. 12, 2007.
EP Search Report for EP03762238 3 pgs, Mailed Jun. 2, 2006.
EP Search Report for EP94916716 2 pgs, Oct. 29, 1996.
EP Search Report for EP96941386 2 pgs, Nov. 27, 1998.
EP Search Report for EP98952032 2 pgs, Nov. 24, 2000.
EP Search Report for EP 03736488 3 pgs, Mailed Jun. 25, 2009.
PCT International Search Report for PCT/US00/07718 1pg, Mailed Sep. 5, 2000.
PCT International Search Report for PCT/US01/16006 1pg, Mailed Aug. 14, 2001.
PCT International Search Report for PCT/US02/31640 1pg, Mailed May 23, 2003.
PCT International Search Report for PCT/US03/04689 1pg, Mailed Sep. 26, 2003.
PCT International Search Report for PCT/US03/12790 1pg, Mailed Aug. 12, 2003.
PCT International Search Report for PCT/US03/20574 1pg, Mailed May 25, 2005.
PCT International Search Report for PCT/US04/22803 1pg, Mailed Apr. 29, 2005.
PCT International Search Report for PCT/US05/07038 1pg, Mailed Sep. 2, 2005.
PCT International Search Report for PCT/US94/05168, 1 pg, Mailed Oct. 18, 1994.
PCT International Search Report for PCT/US96/18505, 3 pgs, Mailed Jan. 17, 1997.
PCT International Search Report for PCT/US98/20768 1pg, Mailed Jan. 20, 1999.
PCT International Search Report for PCT/US98/22327 1pg, Mailed Feb. 9, 1999.
PCT Notif of the Int'l Search Report and Written Opinion for PCT/US09/67001 6 pgs, Mailed Jan. 29, 2010.
PCT IPER for PCT/US01/16006 3pgs, Apr. 16, 2002.
PCT IPER for PCT/US98/22327 4pgs, Aug. 27, 2000.
PCT Written Opinion for PCT/US04/22803 3pgs, Mailed Apr. 29, 2005.
PCT Written Opinion for PCT/US05/07038 3pgs, Mailed Sep. 2, 2005.
UK Search Report for GB0805061.9 1 pg, Jul. 15, 2008.
UK Search Report for GB0921635.9 3pgs, Apr. 12, 2010.
Related Publications (1)
Number Date Country
20150245862 A1 Sep 2015 US